rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    ANIP
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Is ANI Pharmaceuticals (ANIP) A Bargain After Its $560m Deal?
      Nov 8Yahoo FinanceANIP
      ANI Pharmaceuticals (ANIP) Offers $560 Million For Rare Disease Expansion
      Nov 8Yahoo FinanceANIP
      Should ANI Pharmaceuticals (ANIP) Look Undervalued As Results Land And Revenue Guidance Narrows?

      ANI Pharmaceuticals (ANIP) just put fresh numbers on the table, reporting third quarter and nine month 2026 results along with a slight trim to full year revenue guidance that gives investors new data to weigh. At a share price of $67.41, ANI Pharmaceuticals has slipped about 11% over the past 90 days and is down 14% year to date, while the 1 year total shareholder return is lower at 25% in decline. However, the 3 and 5 year total shareholder returns remain positive, suggesting that the...

      Nov 8Yahoo FinanceANIP
      ANI Pharmaceuticals Inc (ANIP) Q3 2026 Earnings Call Highlights: Strong Revenue Growth Offset ...
      Nov 6Yahoo FinanceANIP
      ANI Pharmaceuticals Q3 2026 Earnings Call Transcript
      Nov 5BenzingaANIP
      ANI (ANIP) Reports Q3 Earnings: What Key Metrics Have to Say
      Nov 5Yahoo FinanceANIP
      ANI Pharmaceuticals (NASDAQ:ANIP) reports strong Q3 2026
      Nov 5Yahoo FinanceANIP
      ANI Pharmaceuticals (ANIP) Surpasses Q3 Earnings and Revenue Estimates
      Nov 5Yahoo FinanceANIP
      ANI Pharma to buy Swedish biotech Egetis for $560M
      Nov 5Seeking AlphaANIP
      ANI Pharmaceuticals Reports Third Quarter 2026 Financial Results
      Nov 5Yahoo FinanceANIP
      ANI Pharma earnings up next: Rare disease pivot faces test
      Nov 4Investing.comANIP
      ANI Pharmaceuticals to Present at Upcoming November Investor Conferences
      Nov 3Yahoo FinanceANIP
      ani pharmaceuticals svp & cfo Stephen Carey sells $207,679 in stock
      Oct 31Investing.comANIP
      ANI Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 5, 2026 at 8:00 a.m. ET
      Oct 23Yahoo FinanceANIP
      ANI Pharmaceuticals' Eye-Care Franchise Faces New Competition, Oppenheimer Says
      Oct 22Yahoo FinanceANIP
      ANI Pharmaceuticals launches generic duloxetine capsules
      Oct 19Investing.comANIP
      ANI Pharmaceuticals Announces the Launch of Duloxetine Delayed-Release Capsules
      Oct 19Yahoo FinanceANIP
      Ani pharma president & ceo Lalwani sells shares for $388k
      Oct 16Investing.comANIP
      Ani Pharmaceuticals general counsel Cook sells $36,795 in stock
      Oct 14Investing.comANIP
      ANI Pharma reports positive phase 4 data for Iluvien in non-infectious uveitis

      Ani Pharmaceuticals’ Iluvien uveitis Phase 4 SYNCHRONICITY trial met endpoints, boosting BCVA and reducing CS. Read more here.

      Oct 12Seeking AlphaANIP
      Did FDA Approval of Generic Everolimus Suspension Just Shift ANI Pharmaceuticals' (ANIP) Investment Narrative?
      Oct 7Yahoo FinanceANIP
      Analysts Offer Insights on Healthcare Companies: Stryker (SYK) and ANI Pharmaceuticals (ANIP)

      Detailed price information for Stryker Corp (SYK-N) from The Globe and Mail including charting and trades.

      Oct 7The Globe and MailANIP
      Ani Pharmaceuticals SVP & CFO Stephen Carey sells $208,050 in stock
      Oct 1Investing.comANIP
      Implied Volatility Surging for ANI Pharmaceuticals Stock Options

      Investors need to pay close attention to ANIP stock based on the movements in the options market lately.

      Sep 28Yahoo FinanceANIP
      ANI Pharmaceuticals: Cortrophin’s Q4 Test, With Generics Funding The Build (NASDAQ:ANIP)
      Sep 24Seeking AlphaANIP
      Ocular Therapeutix and ANI Pharmaceuticals Stocks Trade Down, What You Need To Know

      A number of stocks fell in the afternoon session after sentiment in the healthcare sector weakened, as the Centers for Medicare and Medicaid Services moved to cancel Affordable Care Act coverage for roughly 760,000 people and claw back billions in subsidies.

      Sep 23Yahoo FinanceANIPOCUL
      ANI Pharmaceuticals gets FDA approval for generic everolimus
      Sep 23Investing.comANIP
      Oppenheimer initiates ANI Pharmaceuticals stock with Perform rating
      Sep 23Investing.comANIP
      ANI Pharmaceuticals Announces the FDA Approval of Everolimus Tablets for Oral Suspension
      Sep 23Yahoo FinanceANIP
      Oppenheimer Initiates ANI Pharmaceuticals at Perform With $85 Price Target
      Sep 23Yahoo FinanceANIP
      ANI Pharmaceuticals Wins FDA Approval for Generic Everolimus Tablets
      Sep 23Yahoo FinanceANIP
      Ani Pharmaceuticals’ Meredith Cook sells $35,395 in common stock
      Sep 15Investing.comANIP
      Ani Pharmaceuticals director Thoma sells $71,530 in shares
      Sep 15Investing.comANIP
      ANI Pharmaceuticals at Morgan Stanley conference: rare disease push deepens
      Sep 14Investing.comANIPMS
      ANI Pharmaceuticals at Wells Fargo conference: rare disease push gains pace
      Sep 10Investing.comANIPWFC
      ANI Pharmaceuticals (ANIP) Appoints Henry Gosebruch To Its Board

      ANI Pharmaceuticals (NasdaqGM: ANIP) appointed biotechnology executive Henry Gosebruch to its Board of Directors. Gosebruch previously held leadership roles at Lakefront Biotherapeutics, Neumora Therapeutics, and AbbVie. Board member Muthusamy (Samy) Shanmugam resigned from the Board and will continue in key operational roles at ANI Pharmaceuticals. This kind of board refresh is not unique to ANI Pharmaceuticals, and investors who want broader exposure to companies shaped closely by their...

      Sep 4Yahoo FinanceANIP
      ANI Pharmaceuticals to Present at September Investor Conferences

      PRINCETON, N.J., Sept. 03, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with members of the Company’s executive leadership team, will participate in fireside chats at the following upcoming investor conferences: Event2026 Wells Fargo Healthcare Conference DateThursday, September 10, 2026 Time1:30 p.m. ET WebcastClick here EventMorgan Stanley 24th Annual Global Healthcare Co

      Sep 3Yahoo FinanceANIP
      Ani Pharmaceuticals SVP & CFO Stephen Carey sells $207,480 in stock
      Sep 2Investing.comANIP
      Ani Pharmaceuticals CEO sells $401,220 in company stock
      Aug 26Investing.comANIP
      ANI Pharmaceuticals adds Henry Gosebruch to board of directors
      Aug 24Investing.comANIP
      ANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directors

      – Appointment strengthens board as ANI accelerates transformation into a leading Rare Disease Company – PRINCETON, N.J., Aug. 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today reported the addition of Henry Gosebruch to its Board of Directors effective August 19, 2026. Mr. Gosebruch brings over 30 years of corporate strategy, business development and finance experience across the biopharmaceutical sector. “We are excited to add Henry to our Board of

      Aug 24Yahoo FinanceANIP

      This is the newest page. Registered accounts read further back.